A Phase IIB, Open-Label Study of Zirconium Zr-89 Crefmirlimab Berdoxam PET

As presented at the American Association for Cancer Research Annual Meeting on April 11th, 2022, we are delighted to share our poster, titled, "Phase IIB, Open-Label Study of Zirconium Zr-89 Crefmirlimab Berdoxam PET/CT in Subjects with Selected Advanced Malignancies (Melanoma, Merkel Cell, Renal Cell and Non-Small Cell Lung Cancers), Scheduled to Receive Standard-of-Care Immunotherapy, to Predict Response to Therapy".

The poster provides a summary of the design of our Phase IIb iPredict clinical trial which started enrollment in December 2022 and will correlate CD8 imaging with clinical outcome.

Special thanks to authors and contributing authors:

Kim Margolin (St. John’s Cancer Institute Santa Monica, CA), David Hays (CARTI, Little Rock, AK), Delphine L Chen (University of Washington, Seattle, WA), Gary Ulaner (Hoag Hospital, Newport, CA), Michael D Farwell (UPenn, PA) , Ron Korn (ImaginAb, Inglewood, CA and Imaging Endpoints, Phoenix, AZ) Katherine Young (ImaginAb, Inglewood, CA) , Michael R Ferris (ImaginAb, Inglewood, CA), William Le (ImaginAb, Inglewood, CA) and Ian Wilson (ImaginAb, Inglewood, CA)

If you have any questions, or would like to learn more about CD8 imaging and its utility in clinical trials, please contact us at: info@imaginab.com

Poster of our Phase IIB, Open-Label Study of Zirconium Zr-89 Crefmirlimab Berdoxam PET/CT in Subjects with Selected Advanced Malignancies (Melanoma, Merkel Cell, Renal Cell and Non-Small Cell Lung Cancers), Scheduled to Receive Standard-of-Care Immunotherapy, to Predict Response to Therapy.

Download the Poster

Imaging of CD8+ cytotoxic T-cells by Zr-89-Df-IAB22M2C PET/MRI: First clinical experience in patients with metastatic cancer

As published at the AACR conference on April 11, 2022, we are delighted to share, "Imaging of CD8+ cytotoxic T-cells by Zr-89-Df-IAB22MC2C PET/MRI: First Clinical Experience in Patients with Metastatic Cancer:

Special thanks to contributing authors:

Johannes Schwenck, Dominik Sonanini, Walter Ehrlichmann, Gabriele Kienzle, Gerald Reischl, Pascal Krezer, Ian Wilson, Ron Korn, Irene Gonzalez-Menendez, Leticia Quintanilla-Martinez, Ferdinand Seith, Andrea Forschner, Thomas Eigentler, Lars Zender, Martin Röcken, Bernd Pichler, Lukas Flatz, Manfred Kneilling, Christian La Fougere. Department of Nuclear Medicine and Clinical Molecular Imaging, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Cluster of Excellence iFIT (EXC 2180), Eberhard Karls University, Tuebingen, Germany, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tuebingen, Germany, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, Tuebingen, Germany, ImaginAb, Inc., Inglewood, CA, Institute of Pathology and Neuropathology, Comprehensive Cancer Center, Eberhard Karls University, Tuebingen, Germany, Institute of Pathology and Neuropathology, Comprehensive Cancer Center, Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, Tuebingen, Germany, Department of Diagnostic and Interventional Radiology, Eberhard Karls University, Tuebingen, Germany, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Berlin, Germany, Department of Medical Oncology and Pneumology (Internal Medicine VIII), Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, Tuebingen, Germany, Department of Dermatology, Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, Tuebingen, Germany, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies",Eberhard Karls University, Tuebingen, Germany, Department of Dermatology, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, Tuebingen, Germany, Department of Nuclear Medicine and Clinical Molecular Imaging, Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally

If you have any questions, or would like to learn more about CD8 imaging and its utility in clinical trials, please contact us at: info@imaginab.com


Download Poster

Evaluating immune checkpoint blockade treatment efficacy via [89Zr]-CD4 and [89Zr]-CD8 PET imaging in breast cancer mouse models

As published at the AACR conference on April 12, 2022, we are delighted to share, "Evaluating immune checkpoint blockade treatment efficacy via [89Zr]-CD4 and [89Zr]-CD8 PET imaging in breast cancer mouse models"


Special thanks to presenters and contributing authors:

Yun Lu, Hailey Houson, Alessandro Mascioni, Fang Jia, Patrick N. Song, Tiara Napier, Amer M. Mansur, Carlos A. Gallegos, Benjamin M. Larimer, Suzanne E. Lapi, Anna G. Sorace. University of Alabama at Birmingham, Birmingham, AL, ImaginAb, Inc, Inglewood, CA


If you have any questions, or would like to learn more about CD8 imaging and its utility in clinical trials, please contact us at: info@imaginab.com

Poster of Evaluating immune checkpoint blockade treatment efficacy via [89Zr]-CD4 and [89Zr]-CD8 PET imaging in breast cancer mouse models

Download the Poster